comparemela.com

Latest Breaking News On - Cardiovascular risk - Page 7 : comparemela.com

Understanding Comorbidities: Impact on Biologic Treatment Selection

Experts discuss common comorbidities for patients with plaque psoriasis and how they can impact treatment decisions.

Cardiovascular riskComorbid therapeuticsChronic diseasesLifestyle interventionsTreatment monitoring

Are E-Cigarettes Bad for the Heart?

When considering damage to the endothelium and toxicity, e-cigarettes have a negative impact like that of conventional cigarettes.

Baden wübergStefan andreasGerman respiratory societyUniversity of mainzIntensive careReplacement therapiesTobacco cessationUitting tobacco useSmoking cessationTobacco smokeSecondhand smokeSecondhand tobacco smokeMassive smokeEnvironmental tobacco smokeTobacco useCv risk

New Data Question Beta-Blockers Post-MI With Preserved EF

In patients who had revascularization after an acute MI and had a preserved EF, long-term beta-blocker use showed no benefit compared with no beta-blockers, in REDUCE-AMI.

United statesNew zealandWayne batchelorTroels yndigegnVascular institute in fairfaxUniversity hospital in lundInterventional councilAmerican college of cardiologyAmerican collegeNew england journalUniversity hospitalMedscape medical newsInova schar heartVascular instituteMyocardial infarctionCv risk

Preventive PCI for Vulnerable Plaques Reduces Cardiac Events

Preventive PCI plus optimal medical therapy reduced cardiac events and death in patients with non–flow-limiting coronary plaques vs medical therapy.

Soult ukpyolsiSouth koreaNew yorkUnited statesNew zealandThe mountNew zealand generalRepublic of koreaJosipa borovacUniversity of split school medicineDivision of cardiology at asan medical centerUniversity of ulsan college medicineAmerican college of cardiologyIcahn school of medicine at mount sinaiAcademic affairsMount sinai heart health system

Substantial Triglyceride Reduction With Plozasiran

In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.

United statesNorth carolinaNeha pagidipatiDaniel gaudetUniversity of montrealAmerican college of cardiology annual scientific sessionDuke clinical research instituteAmerican collegeAnnual scientific sessionIpid managementCv riskCardiovascular riskV risk factorsCardiovascular risk factorsCardiovascular risk managementAbdominal infection

vimarsana © 2020. All Rights Reserved.